Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent Disease
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Auranofin (Primary) ; Sirolimus (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Jul 2019 Status changed from suspended to active, no longer recruiting.
- 17 Jan 2019 Status changed from recruiting to suspended.
- 02 Apr 2018 Status changed from not yet recruiting to recruiting.